Lampson, B. L., Nishino, M., Dahlberg, S. E., Paul, D., Santos, A. A., Jänne MD, P. A., & Oxnard, G. R. (2016). Activity of erlotinib when dosed below maximum tolerable dose for EGFR-mutant lung cancer: Implications for targeted therapy development. Cancer.
シカゴスタイル引用形Lampson, Benjamin L., Mizuki Nishino, Suzanne E. Dahlberg, Danie Paul, Abigail A. Santos, Pasi A. Jänne MD, , Geoffrey R. Oxnard. "Activity of Erlotinib When Dosed Below Maximum Tolerable Dose for EGFR-mutant Lung Cancer: Implications for Targeted Therapy Development." Cancer 2016.
MLA引用形式Lampson, Benjamin L., et al. "Activity of Erlotinib When Dosed Below Maximum Tolerable Dose for EGFR-mutant Lung Cancer: Implications for Targeted Therapy Development." Cancer 2016.